LifeArc, a London-based medical research charity, is to receive a £1bn windfall after selling most of its royalty interest in cancer drug Keytruda. Professor Robin Ali (UCL Ophthalmology) says this level of potential funding will boost morale among researchers.
Read: FT
Close
